Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ContextVision AB: Year-end report 2023 – Underlying growth and scaling up the business

Q4 Highlights · New advanced X-ray product Altumira™ Plus with scatter correction released · Participation in world’s largest medical imaging conference, Radiological Society of North America (RSNA) · Increasing interest from customers and OEMs in our products · Strategic investments in Point of Care Ultrasound (POCUS), R&D and Quality Management Q4 Financial Data · Record Q4 Net Sales of 33.2 MSEK (32.6) · Operating result of 3.2 MSEK (9.1) · EBITDA of 5.2 MSEK (11.0) · Dividend payout of 11.6 MSEK · Earnings per share of 0.04 SEK (0.10) Full Year

Notice to the Annual General Meeting of Kojamo plc

Kojamo plc Stock Exchange Release, 15 February 2024 at 9.00 a.m. EETNotice to the Annual General Meeting of Kojamo plc Notice is given to the shareholders of Kojamo plc to participate in the Annual General Meeting to be held on Thursday 14 March 2024 at 10.00 a.m. (EET) in Pikku-Finlandia at Karamzininranta 4, Helsinki, Finland. The reception of participants and the distribution of ballots will commence at the meeting venue at 9.00 a.m. (EET). Shareholders and their proxy representatives may also exercise voting rights by voting in advance. Instructions for advance voting are presented

Frida Norrbom Sams and Mark Williamson proposed as new members of the board of directors of Concentric AB

The nomination committee of Concentric AB proposes that Frida Norrbom Sams and Mark Williamson are elected as new members of the board of directors at the annual general meeting on April 18, 2024. The nomination committee further proposes that Anders Nielsen, Claes Magnus Åkesson, Karin Gunnarsson, Petra Sundström, Martin Sköld and Joachim Rosenberg are re-elected. The current board member Susanna Schneeberger has informed the nomination committee that she declines re-election. The nomination committee’s proposal means the board will consist of eight members elected by the general

Implantica’s RefluxStop™ now available in Munich

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the first RefluxStop™ procedures completed at Artemed Klinikum München Süd in Munich, Germany.Prof. Thomas Mussack, Chief Physician and Medical Director of the Department of Surgery at Artemed Klinikum München Süd, performed two successful RefluxStop™ procedures to treat severe GERD. Today, both patients have returned to eating normally and are well treated. Prof. Mussack says, “I appreciate how RefluxStop™ restores the body’s natural anatomy to solve the root problem of

Polygiene Group AB (publ.) Interim Report October 1 – December 31, 2023

SIGNS OF RECOVERY AND POSITIVE MARKET SIGNALS Net sales for the quarter amounted to MSEK 30.9 (40.0), down 23 % from the same period in 2022. This period saw a solid gross margin of 70.6 (64.9) %. Operating profit before interest, taxes, depreciation, and amortization (EBITDA) came to MSEK -3.4 (-1.8) million, including one-off costs of MSEK 3.7. Cash flow was negative at MSEK -2.3 million (-4.1 adjusted for foreign currency effects), and cash and cash equivalents totaled MSEK 44.1.Financial development during the quarter · Net sales amounted to MSEK 30.9 (40.0). There is an

Esmaeilzadeh Holding publishes net asset value as of 31 January 2024

As of 31 January 2024, the net asset value for Esmaeilzadeh Holding AB (publ) was SEK 7.14 billion (SEK 7.16 billion as of 31 December 2023), corresponding to a net asset value per share of SEK 9,268 (SEK 9,294 as of 31 December 2023).[1] For further information, please contact: Mikael Ericson, CEO mikael.ericson@ehab.group Nils Fredrik Lagerstrand, General Counsel & Deputy CEO +46 720 90 26 99, nilsfredrik@ehab.group The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 15 February 2024. About

Motion to 2024 Annual General Meeting in JM AB regarding Chair and Board Members

The Nomination Committee of JM AB has decided to propose the following to the 2024 Annual General Meeting regarding the composition of the Board of Directors.Number of Board Members: Seven ordinary Members.   The Nomination Committee proposes the re-election of Fredrik Persson as Chair of the Board. The Nomination Committee furthermore proposes the re-election of Members Stefan Björkman, Kerstin Gillsbro, Jenny Larsson, Olav Line, Thomas Thuresson and the new-election of Liia Nõu. Camilla Krogh has declined re-election. Liia Nõu, born in 1965, is currently the CEO of Pandox. Before

Year-end report 1 January – 31 December 2023

January – December · Revenue amounted to SEK 589.7 million (501.6), a year-on-year increase of 18 per cent. · Net operating income for the period amounted to SEK 337.2 million (278.9), a year-on-year increase of 21 per cent. · Profit from property management amounted to SEK 124.2 million (113.4), a year-on-year increase of 10 per cent. · Changes in the value of investment properties amounted to SEK -439.9 million (-25.7) and changes in the value of derivatives to SEK -139.8 million (95.9). · Earnings totalled SEK -381.5 million (125.1), corresponding to SEK -2.91 per share (

Interim Report January – December 2023: Continued sustainable and profitable expansion and a strong financial position

Our growth journey continued during the fourth quarter. SLP can report another strong quarter driven by continued acquisitions, new construction projects, and new and extended rental agreements with satisfied tenants.· Rental income increased by 42%, amounting to SEK 585 m (411). · Net operating income increased by 49%, amounting to SEK 487 m (327). · Profit from property management increased by 36% and amounted to SEK 303 m (222). · Earnings per share after dilution amounted to SEK 1.55 (2.39). · Net asset value (NAV) per share after dilution increased by 15% in the

Interim Report Q4, 2023

“Storytel continued its transformation journey and delivered yet another strong quarter to conclude 2023”, says Johannes Larcher, CEO, Storytel.Financial Highlights Q4 Fourth quarter 2023 compared to the fourth quarter 2022 · Streaming revenue up 16% to 858 (742) MSEK; or 14% at constant exchange rates (CER) · Group revenue increased by 9% to 946 (867) MSEK  · Adjusted Gross profit up 20% to 387 (322) MSEK, equaling a margin of 40.9% (37.2%)  · Gross profit was down 24% to 246 (322) MSEK · Adjusted EBITDA increased by 62% to 86 (53) MSEK, equaling a margin of 9.1% (6.1%)

Year-end report 1 January–31 December 2023

A strong quarter and year for Arise! CEO comment:When summarising the fourth quarter, I can note that we continue to deliver good results. Income from the sale of the Fasikan project in combination with historically high income from our production means that all together, the quarter was very strong, with profit after tax of MSEK 77. Fourth QUARTER (1 October–31 December 2023) · Net sales for the quarter amounted to MSEK 191 (106). · Operating profit before depreciation and amortisation (EBITDA) was MSEK 82 (52). · Operating profit (EBIT) was MSEK 65 (37). · Profit

Tietoevry's Interim Report 4/2023: Resilient performance in a mixed market

Tietoevry Corporation FINANCIAL STATEMENT RELEASE 15 February 2024, 9.00 a.m. (EET)  ·Growth 1% – solid underlying performance in software businesses continued ·Healthy profitability of over 14% supported by efficiency measures ·Strategic review of Banking – demerger proposed to list the business, retaining optionality for other alternatives – sales process ongoing in parallel in light of market interest ·Strategic review of Tech Services – on track with previously announced schedule, active engagement with potential buyers ·Increased dividend of EUR 1.

Transaction in Own Shares

    15 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |14/02/2024|+----------------------------------------------------------

Directorate Change

      15 February 2024 Vesuvius plc Non-executive Director Changes   Vesuvius plc, a global leader in molten metal flow engineering and technology, is pleased to announce the proposed appointment of Eva Lindqvist as a Non-executive Director. Eva will be appointed to the Company’s Board with effect from the close of the Company’s Annual General Meeting (‘AGM’) to be held on 15 May 2024, subject to her election being approved by the Company’s shareholders at the AGM. On her appointment, Eva will also join the Company’s Audit, Remuneration and Nomination Committees.

Vianode selected IPCEI EUBatin associated partner to support accelerated industrialisation of Europe’s battery value chain

Vianode, an advanced battery materials company providing sustainable anode graphite solutions, has been selected as an associated partner in the EU’s Important Projects of Common European Interest (IPCEI) EUBatin program to support accelerated industrialisation of a low-carbon battery value chain.The transnational IPCEI program aims to bring green transition innovations to market at scale more quickly through European industrial cooperation, public-private partnerships and possibilities to offer exemptions from public support regulations. IPCEI EUBatin is the second part of a two-stage

Lehto Group Plc, inside information: Lehto files for corporate restructuring

Lehto Group PlcInside information15 February 2024 at 9:00 (Finnish time)The Board of Directors of Lehto Group Plc (”Lehto”) has decided to file for corporate restructuring proceedings at the district court of Oulu. Throughout 2023, Lehto has disclosed its difficult financial situation, which has been exacerbated by the challenging market situation in the construction industry. The operative subsidiaries of Lehto, Lehto Asunnot Oy, Lehto Tilat Oy, and Lehto Korjausrakentaminen Oy, have been declared bankrupt on 8 February 2024 due to which the operative cash flow of Lehto has mainly

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark.The company’s gross margin was 38.9 per cent for the year, down from 42.8 per cent in the year before. Adjusted EBITDA (EBITDA less acquisition cost) amounted to NOK 51.6 million, compared with

Peab builds railway sidings in Gothenburg

Peab has been commissioned to build new railway sidings in Lärje, north of Gothenburg, for local and regional trains. The customer is the Swedish Transport Administration and the contract is worth SEK 392 million.The project is part of the Swedish Transport Administration’s program to increase capacity and accessibility for train traffic in the Gothenburg area. The opening of Västlänken will change train traffic and more trains will need to be stored when not in use. Lärje has been identified as suitable place for a siding primarily due to its proximity to the central railway network,

Careium reports fourth quarter results 2023

The quarter in summary · Net sales amounted to SEK 199.4 million (196.2), an increase of 1.7 percent. Service sales amounted to 154.1 million (145.1), an increase of 6.2 percent. Product sales amounted to 45.3 million (51.1), a decrease of 11.3 percent. · Gross margin amounted to 40.2 percent (39.4). · Operating profit (EBIT) amounted to SEK 16.7 million (13.2), corresponding to an operating margin of 8.4 percent (6.7). The EBIT last year was positively affected by SEK 3.9 million from non-recurring items. · Free cash flow amounted to SEK 35.8 million (-53.4). · Earnings

INSIDE INFORMATION: Tietoevry’s strategic review of its Banking business: Tietoevry’s Board of Directors has approved a demerger plan

Tietoevry Corporation   INSIDE INFORMATION   15 February 2024, 9:00 a.m. EET   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.   INSIDE INFORMATION: Tietoevry’s strategic review of its Banking business: Tietoevry’s Board of Directors has approved a demerger plan   · Separation process of Tietoevry Banking continues: demerger plan concerning a partial demerger of

Prostatype Genomics publishes year-end report for 2023

Prostatype Genomics AB today publishes its year-end report for the full year 2023, including the interim report for the second half of 2023. The full year-end report is attached and can also be downloaded from the company’s website, www.prostatypegenomics.com.Summary of the second half of the year and the full year 2023 Second half of 2023, 1 July 2023 – 31 December 2023• Net sales amounted to 908 TSEK (414)• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -17,797 TSEK (-14,849)• Cash flow from current operations amounted to -9,938 TSEK (-16,386)

Optomed Plc: Financial Statements Bulletin, January – December 2023

Optomed Plc         Stock Exchange Release    15 February 2024 at 9:00, Helsinki Optomed Plc: Financial Statements Bulletin, January – December 2023 October – December 2023 · Revenue decreased by 8.8 percent to EUR 3.7 (4.0) million. · Devices segment revenue decreased by 19.8 percent to EUR 1.0 (1.3) million. · Software segment revenue decreased by 3.7 percent to EUR 2.6 (2.7) million. · EBITDA and adjusted EBITDA amounted to EUR -0.8 (-0.3) million corresponding to -20.7 (-8.7) percent of revenue. · Optomed expects its full year 2024 revenue to grow compared to 2023.

Interim report January - December 2023

Summary of a new record year Quarter 4, 2023   · Orders received amounted to SEK 1,467m (1,396), equivalent to currency neutral growth of 4.8 percent compared with the same period last year. · Net sales amounted to SEK 1,501m (1,515), equivalent to a currency neutral decline of 0.8 percent compared with the same period last year. · Adjusted EBITA was SEK 171.6m (161.1), giving an adjusted EBITA margin of 11.4 percent (10.6). · Operating profit amounted to SEK 149.2m (136.8), corresponding to an operating margin of 9.9 percent (9.0). · Net profit was SEK 77.3m (90.9).

There are no items matching the current filter
There are no more items matching the current filter
Back to top